National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 61 of 66
4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
NCT00003853
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
NCT00003895
A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
NCT00001812
Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
NCT00003873
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019721
Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00003850
Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma
NCT00003778
Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer
NCT00003869
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00003665
Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples
NCT00001814
O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
NCT00003613
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
NCT00001805
Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
NCT00003694
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00019591
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
NCT00003350
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
NCT00003789
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
NCT00019695
Von Hippel-Lindau Disease Genetic Epidemiology Study
NCT00001803
Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families
NCT00341627
Eflornithine in Treating Patients With Bladder Cancer
NCT00003814
Extended Follow-up of Columbia, MO Serum Bank Participants
NCT00340210
A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal Miners
NCT00342264
Vaccine Therapy in Treating Patients With Melanoma
NCT00003556
A Phase II Evaluation of Telesurgery Systems
NCT00026923
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma
NCT00003970
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
NCT00330382
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
NCT00001797
Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma
NCT00003575
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
NCT00003595
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
NCT00004038
Raloxifene in Preventing Breast Cancer in Premenopausal Women
NCT00019500
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
NCT00021983
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019487
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT00019539
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
NCT00001790
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00019552
Gene Therapy in Treating Patients With Ovarian Cancer
NCT00003588
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00019448
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT00003545
Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
NCT00003288
Irofulven in Treating Children With Recurrent or Refractory Solid Tumors
NCT00003370
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
NCT00003439
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
NCT00003451
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
NCT00001703
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection
NCT00001701
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection
NCT00001702
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
NCT00118365
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic
NCT00003440
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
NCT00001705
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00026910
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.